Trelegy Ellipta 62.5 ug/1

Trelegy Ellipta 62.5 ug/1 is a combination inhaler containing fluticasone furoate, umeclidinium bromide, and vilanterol trifenatate. It is designed for respiratory conditions, offering a convenient once-daily treatment option. This inhaler is manufactured by GlaxoSmithKline LLC and is available in a 30-dose pack.

Trelegy Ellipta 62.5 ug/1 is primarily used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma. The combination of fluticasone furoate, umeclidinium bromide, and vilanterol trifenatate works to reduce inflammation, relax airway muscles, and improve breathing. This inhaler is often prescribed for individuals who require a combination of these active ingredients to manage their respiratory symptoms effectively.

Common effects of Trelegy Ellipta 62.5 ug/1 may include throat irritation, headache, and a dry mouth. Some users might experience hoarseness or a cough shortly after inhalation. These effects are generally mild and temporary, but if they persist or worsen, it is advisable to consult a healthcare professional.

Trelegy Ellipta 62.5 ug/1 should be used as directed by a healthcare professional. It is important to follow the prescribed dosage and administration instructions to ensure safety and effectiveness. Patients with certain medical conditions, such as severe asthma or heart problems, should discuss their use of this inhaler with their doctor before starting treatment.

Trelegy Ellipta 62.5 ug/1 may interact with other medications, including beta-blockers, diuretics, and certain antibiotics. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Additionally, the use of alcohol or other respiratory depressants should be discussed with a healthcare professional.